Introduction to the efficacy, functions and indications of Anagrelide

Anagrelide (Anagrelide) is a platelet-lowering drug that has been used for a long time in many countries around the world. It is mainly used in the management of thrombocythemia (ET) secondary to myeloproliferative neoplasms. With the deepening of the understanding of the mechanism of thrombocythemia, international guidelines gradually regard anagrelide as one of the important cytoreductive treatment options. Its unique mode of action allows it to specifically regulate the platelet production process, thereby reducing the risk of thrombosis caused by excessive platelet elevation and improving various symptoms caused by high viscosity in the circulatory system.

At the level of pathological mechanism, thrombocytosis is often related to abnormal activity of the bone marrow hematopoietic system, and this type of disease is usually classified as myeloproliferative neoplasm. Abnormally elevated platelet counts can lead to increased blood coagulation tendencies, the formation of thrombosis, microcirculatory disorders, and even an increased risk of cardiovascular and cerebrovascular events. The core advantage of anagrelide is that it can selectively affect megakaryocyte development, thereby reducing the excessive production of platelets. It does not have obvious inhibitory effects on other blood lines like some traditional cytostatic drugs, so it is generally more tolerable in long-term treatment.

Anagrelide is considered to be a "strongly targeted" platelet-lowering drug. Its point of action is mainly focused on the differentiation of megakaryocytes to the mature stage, especially exerting an inhibitory effect on the cytoplasmic proliferation stage of mature megakaryocytes. By reducing the number of mature megakaryocytes, the production of platelets naturally decreases, achieving a sustained and stable control effect. Since the drug does not directly destroy existing platelets, its decline is usually gradual and relatively smooth, making it more suitable for patients who require mid- to long-term maintenance therapy.

In terms of clinical indications, anagrelide is mainly used to treat thrombocythemia secondary to myeloproliferative tumors, such as chronic proliferative diseases that are common in some patients. The more representative ones include essential thrombocythemia (ET) and some of the elevated platelets that accompany the early stages of myelofibrosis. The purpose of its treatment is not only to reduce platelet count, but more importantly, to reduce the risk of thrombotic events, such as deep vein thrombosis, cardiovascular and cerebrovascular obstruction, and microcirculatory ischemia symptoms.

In addition to reducing the risk of thrombosis, anagrelide can effectively improve some clinical manifestations caused by high platelet status. For example, some patients may have symptoms related to microcirculation disorders such as headache, dizziness, numbness of limbs, burning sensation in blood flow, blurred vision, etc. These symptoms will usually be relieved after the platelet count gradually decreases. Some data also point out that for patients with repeated bleeding (especially superficial mucosal and skin bleeding) due to high platelet count, controlling the platelet count can also help improve the frequency of bleeding and reduce inconvenience and risks in life.

In recent years, with the promotion of precision medicine and risk stratification concepts, the use strategy of anagrelide in patients with different risk levels has become more clear. For example, for some high-risk patients (such as older patients or those with cardiovascular risks), anagrelide is often used in conjunction with other treatments to achieve a more balanced platelet control target. For some low- and medium-risk patients, single drug treatment can achieve effective maintenance effects, which also reflects its flexibility in treatment options.

References: https://go.drugbank.com/drugs/DB00261